What Birth Control Causes Weight Loss? An Evidence Review of Hormonal Contraception and Body Weight (2026)

Almost no birth control reliably causes meaningful weight loss. That is the honest answer the published evidence supports. The two Cochrane systematic reviews on the topic — Lopez 2016 on progestin-only contraceptives (PMID 27567593) and Gallo 2014 on combination contraceptives (PMID 24477630) — both concluded the available evidence is insufficient to establish a causal effect of hormonal contraception on weight, with most studies showing weight-neutral outcomes. The asymmetry actually goes the opposite direction from what the search query suggests: depot medroxyprogesterone (Depo-Provera) is associated with meaningful weight gain (Dianat 2019, PMID 30633132). Hormonal IUDs (Mirena, Kyleena) show weight changes comparable to copper IUDs — i.e., effectively weight-neutral. If meaningful weight loss is your primary goal, the evidence-based options are FDA-approved anti-obesity medications, not hormonal contraception.

The honest answer first

The search query “what birth control causes weight loss” gets searched roughly 1,200 times per month in the United States, and a handful of related queries (which birth control makes you lose weight, birth control for weight loss, weight-loss-friendly birth control) pull the cluster north of 1,500. Most of the content that ranks for those queries gives readers a flattering version of the answer they came looking for — implying that switching to a specific pill or method might reliably take pounds off.

The evidence does not support that. Two Cochrane systematic reviews — the gold standard in evidence synthesis — looked at every randomized trial and prospective cohort study they could find on hormonal contraception and weight, and both concluded the same thing: the data are insufficient to establish that hormonal contraception causes weight change in either direction, and the studies that do find effects show them to be small.

That doesn't mean nobody loses weight while on a given contraceptive — some people do, but the cause is almost always something else (lifestyle change, time-coincident health change, regression to the mean, water weight fluctuation around starting or stopping a hormone). It also doesn't mean weight gain on contraception is imaginary — some methods, especially depot medroxyprogesterone, are associated with documented weight gain. The asymmetry is important: the evidence on weight gain for some methods is stronger than the evidence on weight loss for any method.

What the Cochrane reviews actually found — progestin-only

Lopez et al. published the most recent Cochrane systematic review of progestin-only contraceptives and weight in 2016 (Cochrane Database Syst Rev., CD008815, PMID 27567593). They pooled 22 studies of progestin-only pills, the etonogestrel implant (Implanon / Nexplanon), depot medroxyprogesterone (DMPA / Depo-Provera), the levonorgestrel intrauterine system (Mirena and similar), and progestin-only injectable formulations.

Their verbatim conclusion:

“We considered the overall quality of evidence to be low; more than half of the studies had low quality evidence. The main reasons for downgrading were lack of randomizations (NRS) and high loss to follow-up or early discontinuation. These 22 studies showed limited evidence of change in weight or body composition with use of POCs. Mean weight gain at 6 or 12 months was less than 2 kg (4.4 lb) for most studies. Those with multiyear data showed mean weight change was approximately twice as much at two to four years than at one year, but generally the study groups did not differ significantly. Appropriate counseling about typical weight gain may help reduce discontinuation of contraceptives due to perceptions of weight gain.”

— Lopez et al., Cochrane Database Syst Rev. 2016;(8): CD008815. PMID 27567593

Three things stand out in that conclusion. First, the average weight change at 6–12 months was less than 2 kg (4.4 lb) — small, in the same noise band as ordinary year- to-year weight fluctuation in adult women not on hormonal contraception. Second, where weight change did occur, it was directional toward gain, not loss. And third, the Cochrane authors specifically called out perceptions of weight gain as a driver of contraceptive discontinuation — i.e., patients believe these methods cause weight change more often than the data support.

What the Cochrane reviews actually found — combination contraceptives

Gallo et al. published the parallel Cochrane systematic review of combination (estrogen + progestin) contraceptives and weight in 2014 (Cochrane Database Syst Rev., CD003987, PMID 24477630). They pooled 49 trials of combined oral contraceptives (the pill), the contraceptive patch (Ortho-Evra / Xulane), and the vaginal ring (NuvaRing / Annovera).

Their verbatim conclusion:

“Available evidence was insufficient to determine the effect of combination contraceptives on weight, but no large effect was evident. Trials to evaluate the link between combination contraceptives and weight change require a placebo or non-hormonal group to control for other factors, including changes in weight over time.”

— Gallo et al., Cochrane Database Syst Rev. 2014;(1): CD003987. PMID 24477630

The Gallo review applies to combined oral contraceptives broadly — there is no evidence that any specific COC formulation (Yaz, Yasmin, Loestrin, Levlen, Ortho Tri-Cyclen, etc.) produces weight loss. Marketing materials and patient anecdotes have at various times suggested that drospirenone-containing pills (Yaz, Yasmin) cause weight loss because drospirenone has a mild diuretic effect. The diuretic effect is real but small (a few hundred grams of water weight, not body fat), and the Cochrane review did not find a clinically meaningful weight-loss signal.

Method-by-method evidence summary

Across every column of that table, no row says “weight loss.” That is the honest summary of the evidence. The question “what birth control causes weight loss” does not have a clean clinical answer because no method reliably produces meaningful weight loss.

Depo-Provera and weight gain — the documented asymmetry

Depot medroxyprogesterone acetate (DMPA / Depo-Provera) is the one hormonal contraceptive where the weight-effect signal goes meaningfully in one direction — toward weight gain. Dianat et al. (2019, Obstet Gynecol., PMID 30633132) systematically reviewed the side effects of DMPA and concluded:

“Studies of moderate or high risk of bias suggest an association between DMPA use and weight gain, increased body fat mass, irregular bleeding, and amenorrhea.”

— Dianat et al., Obstet Gynecol. 2019;133(2):332-341. PMID 30633132

The Cochrane Lopez 2016 review (PMID 27567593) pooled DMPA data with the rest of the progestin-only methods and found the same broad direction: where weight changes occurred, they skewed toward gain, not loss, and DMPA users showed the largest mean changes within the progestin-only group. Patient education materials and the Pfizer Depo-Provera label explicitly disclose weight gain as a recognized side effect.

This is the asymmetry that matters for the search query. “Birth control that causes weight loss” has no clean evidence-based answer; “birth control that causes weight gain” has at least one — DMPA. Patients on Depo-Provera who are concerned about weight gain should discuss alternatives with their prescriber. A switch to a weight-neutral method (combined oral contraceptive, hormonal IUD, copper IUD, implant) is a clinically reasonable decision; the choice has to balance contraceptive efficacy, bleeding pattern, medical contraindications, and side effects — not weight alone.

Hormonal IUDs and minimal systemic exposure

The levonorgestrel intrauterine system (Mirena, Kyleena, Liletta, Skyla) deserves a separate note because it is the hormonal contraceptive with the smallest systemic hormone exposure. Mirena releases roughly 20 micrograms of levonorgestrel per day directly into the uterine cavity, with a small fraction making it into systemic circulation. That low systemic exposure is the mechanistic reason hormonal IUD users show weight changes that are essentially indistinguishable from copper IUD users (no hormone exposure at all) — the hormone effect is swamped by the underlying background variation in body weight over time.

Dal'Ava et al. (2012, Contraception, PMID 22445431) directly compared body weight and body composition among LNG IUD users and concluded the weight changes were similar to those associated with copper intrauterine devices — i.e., not attributable to the hormone. Cochrane Lopez 2016 reached the same conclusion when LNG-IUS data were pooled with other progestin-only methods.

Practically: if you are choosing between hormonal contraceptive methods and weight-neutrality is one of your decision factors, hormonal IUDs are the most weight-neutral of the hormonal options. They will not cause weight loss — but they are the closest to neutral.

Why the search demand exists (and what it's really asking)

The “birth control that causes weight loss” query gets ~1,200 monthly U.S. searches not because there is a weight-loss-causing contraceptive; it gets searched because of three real patient situations:

• Patients on Depo-Provera who gained weight and are considering a switch to something they hope will reverse the gain. The honest answer is that switching off DMPA can stop further DMPA-attributable gain, but the replacement method will not actively cause weight loss.
• Patients with PCOS or insulin resistance who have read that their condition is associated with weight gain and that hormonal contraception is part of PCOS management, and are asking whether a specific contraceptive choice could double as a weight intervention. (Combined oral contraceptives are part of the PCOS dermatologic and gynecologic regimen — but for hyperandrogenism, hirsutism, and cycle regulation, not for weight loss. See our PCOS evidence guide for what actually works.)
• Patients who have heard or read that drospirenone- containing pills (Yaz / Yasmin) cause weight loss because of drospirenone's mild diuretic effect. The diuretic effect is real but produces water-weight changes measured in hundreds of grams, not the multi-kg loss patients are typically hoping for.

The honest service to all three patients is the same: the evidence does not support meaningful weight loss from any hormonal contraceptive. If weight loss is a primary goal, the conversation belongs in a different framework — diet, physical activity, and where appropriate, FDA-approved anti-obesity medications.

What is not evidence — anecdotal weight loss reports

Two distinctions matter for any patient reading testimonial or social-media-driven content about contraception and weight:

1. Personal experience is not evidence of causation. A patient who started a new pill and lost 8 lb over the following 3 months was almost certainly losing weight because of something else — a diet change, increased activity, an unrelated illness, or simple regression-to-the-mean from a starting weight that was temporarily elevated. The same Cochrane reviews above looked at thousands of patients across dozens of studies and could not detect a population-level signal large enough to be clinically meaningful — which means the per-patient stories that look causal are mostly noise.
2. Stopping a method that caused weight gain is not the same as a method causing weight loss. A patient who gained 6 lb on Depo-Provera and lost most of it after switching to a copper IUD did not lose weight because of the copper IUD — they reverted to their pre-DMPA baseline. The reversion is real and meaningful for that patient, but it is not evidence that copper IUDs cause weight loss.

If weight loss is your primary goal

If meaningful weight loss is your primary goal, the evidence-based options are not hormonal contraception. They are:

• Lifestyle interventions — caloric deficit, increased physical activity, sleep optimization, reduction in ultra-processed food intake. The 5–10% body-weight loss range typically achievable through lifestyle change alone is meaningful for most metabolic and reproductive health outcomes (cycle regularity in PCOS, insulin resistance, blood pressure, lipid profile). It is also the foundation that every pharmacologic intervention builds on.
• FDA-approved anti-obesity medications for patients meeting BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity). Current options include the GLP-1 receptor agonists Wegovy (semaglutide 2.4 mg/week, −14.9% mean body weight at 68 weeks in STEP 1), Zepbound (tirzepatide 5–15 mg/week, up to −20.9% at 72 weeks in SURMOUNT-1), Saxenda (liraglutide 3 mg/day), Foundayo (orforglipron, oral once-daily, the first oral GLP-1 approved for weight management), and the older non-GLP-1 agents (phentermine, Qsymia, Contrave). These produce the kind of meaningful weight reduction the “birth control for weight loss” query is reaching for.
• Bariatric / metabolic surgery for patients with BMI ≥ 35 (with comorbidities) or ≥ 40, where the weight reductions are larger and more durable than any pharmacologic option (see our bariatric surgery vs GLP-1 decision guide).

These are different problems with different solutions. Contraception is for preventing pregnancy. Anti-obesity medications and lifestyle/surgical interventions are for weight management. Conflating the two — picking a contraceptive method based on hoped-for weight effects — risks under-protecting against unintended pregnancy AND under-treating obesity, neither of which serves the patient.

Contraception and GLP-1 use — the inverse question

There is a related question that does have a clinically meaningful answer, and it goes the opposite direction: can a GLP-1 weight-loss drug affect the bioavailability of an oral contraceptive? Yes — for tirzepatide (Mounjaro/Zepbound) and orforglipron (Foundayo) specifically. Per the FDA labels:

• Mounjaro and Zepbound (tirzepatide) Section 7.2 + Section 8.3: women on combined oral contraceptives must switch to a non-oral method or add a barrier method for 4 weeks after starting tirzepatide AND for 4 weeks after each dose escalation. The mechanism is delayed gastric emptying altering oral pill absorption.
• Foundayo (orforglipron) Section 7.3 + Section 8.3: 30-day backup-contraception requirement starting at initiation, with the same mechanism (oral drug co-localizing with the oral pill in the GI tract).
• Wegovy and Ozempic (semaglutide) and Saxenda (liraglutide): no oral- contraceptive warning. The PK studies (Kapitza 2015 PMID 25475122 for semaglutide; the liraglutide PK package) did not show clinically meaningful reductions in oral contraceptive bioavailability.

Full details and verbatim FDA-label quotes are in our companion article on Mounjaro & Zepbound + birth control evidence. If you are on tirzepatide or Foundayo and want oral contraception, do not skip this article — the backup- contraception window is real and labeled.

PCOS context — when weight and contraception decisions intersect

Polycystic ovary syndrome (PCOS) is the patient context where contraception and weight management most often intersect. Combined oral contraceptives are part of the conventional PCOS regimen — for hyperandrogenism, hirsutism, acne, and cycle regulation, not for weight loss. The 2023 International PCOS Guideline endorses combined oral contraceptives as first-line pharmacologic management for the dermatologic and gynecologic features of PCOS.

For PCOS-associated obesity, the evidence-based pharmacologic options are metformin and GLP-1 receptor agonists (Wegovy, Zepbound, Foundayo) — not contraception. The Hollanda Morais 2024 meta-analysis pooled 4 RCTs of GLP-1s in obese PCOS patients and found BMI −2.42, waist −5.16 cm, and total testosterone −1.33 nmol/L. Carmina 2023 reported 80% menstrual-cycle restoration on semaglutide. PCOS patients often end up on both — a combined oral contraceptive for hyperandrogenism plus a GLP-1 for weight — at the same time. See our dedicated PCOS evidence + insurance guide for the full primary-source review.

Two notes for PCOS patients specifically:

• The combined oral contraceptive is for the hyperandrogenism / cycle / acne piece, not for weight. Do not expect a COC to cause weight loss; do expect it to help with hirsutism, acne, and cycle regularity.
• GLP-1s are pregnancy-contraindicated. PCOS patients who want to conceive will have to discontinue a GLP-1 at least 2 months pre-conception per the Wegovy and Zepbound labels — and rapid GLP-1-driven ovulation restoration in PCOS patients means some couples conceive faster than they expect. Effective contraception during the GLP-1 treatment window is non-optional if pregnancy is not the goal.

Contraception decisions belong in a contraceptive-counseling framework

The ACOG Practice Bulletin No. 206 (Use of Hormonal Contraception in Women With Coexisting Medical Conditions, 2019) frames hormonal contraception choice around contraceptive efficacy, the patient's medical history, contraindications (the U.S. Medical Eligibility Criteria for Contraceptive Use category 3 and 4 conditions), bleeding pattern preference, and side-effect profile. Weight effect is one consideration among many — and the evidence base for most methods supports framing them as weight-neutral, not weight-modifying.

Concretely, this means:

• Do not stop a contraceptive method for weight loss reasons without first discussing with your prescriber. The method is preventing pregnancy; stopping creates immediate pregnancy risk that has to be planned for.
• Do not start a specific contraceptive expecting weight loss. The Cochrane evidence does not support that expectation for any hormonal method.
• If you have gained meaningful weight on Depo-Provera specifically and are concerned, that is a clinically reasonable conversation to have with your prescriber. The DMPA + weight-gain association is real. Switching to a weight-neutral method is reasonable; it will not cause weight loss but it can stop further DMPA-attributable gain.
• If your goal is weight loss, address it directly. Lifestyle, FDA-approved anti-obesity medications, and where appropriate bariatric surgery are the evidence-based options.

Bottom line

No hormonal contraceptive reliably causes meaningful weight loss. Both Cochrane systematic reviews — Lopez 2016 on progestin-only methods (PMID 27567593) and Gallo 2014 on combination contraceptives (PMID 24477630) — concluded the available evidence is insufficient to establish a weight-change effect, and where effects exist they are small. The asymmetry runs the opposite direction from the search query: depot medroxyprogesterone (Depo-Provera) is associated with documented weight gain (Dianat 2019, PMID 30633132). Hormonal IUDs (Mirena, Kyleena) are weight-neutral. If meaningful weight loss is your primary goal, the evidence-based options are FDA-approved anti-obesity medications and lifestyle interventions, not hormonal contraception. Contraception decisions should be made with your prescriber on the basis of efficacy, contraindications, bleeding pattern, and overall side- effect profile — weight should not be the deciding factor for most patients, and it should not be the basis for stopping or starting a method without prescriber input.

Related research

• Mounjaro & Zepbound + birth control: the inverse question (does the GLP-1 reduce contraceptive bioavailability)
• GLP-1 pregnancy, PCOS, fertility & women's health (broader scope)
• GLP-1, menstrual cycle, period changes & hormones
• GLP-1s for PCOS — the off-label evidence base
• Best FDA-approved appetite suppressants (2026)
• Qsymia (phentermine + topiramate) — evidence review
• Bariatric surgery vs GLP-1 — decision guide
• FDA-approved weight-loss medications hub